CION Ameerpet
Pancreatic Cancer · Hereditary Risk & Genetics · Reviewed by CION Oncologists
Pancreatic cancer family testing — what your relatives should do next
A gene change found in one person is information for the whole family. Cascade testing is how that information reaches the people it also concerns — one ring of relatives at a time, with a targeted test rather than a repeat of the whole panel. This page explains who to test first, and what each answer changes.
- A targeted test, not the whole panel — the laboratory already knows exactly which change to look for.
- One ring of relatives at a time — first-degree relatives first; a negative branch closes the branch below it.
- A negative result here really counts — a true negative for a change already known in the family is genuinely reassuring.
- Carrying it is a raised risk, not a forecast — most people who carry one of these changes never develop pancreatic cancer.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Happens to the Rest of the Family Once a Gene Change Is Found
Somebody in your family has been tested, and a report has come back naming a gene — often BRCA2, sometimes BRCA1, PALB2, ATM, CDKN2A or one of the Lynch-syndrome mismatch repair genes. The person who was tested has been given a plan. Everyone else has been given a sentence: your relatives should be tested too. That sentence is where most families stall, because nobody explains who, in what order, or what any of it would change.
The formal name for what follows is cascade testing, and pancreatic cancer family testing is the same thing described from the family's side. The principle is simple. The laboratory already knows exactly which change to look for, so relatives are not put through the whole panel again. They are offered a targeted test that reads one specific place in one specific gene, and answers one question: do you carry the family's change, yes or no.
Two facts make the rest of this page easier to read. The first is the arithmetic of inheritance. These gene changes are passed on in a dominant pattern, which means every child, brother and sister of the person who carries it has a one-in-two chance of carrying it too — and it travels down the father's side exactly as readily as the mother's. The second is the limit of what a positive result means. Carrying an inherited change raises the chance of cancer; it does not schedule one. Most people who carry one of these changes never develop pancreatic cancer, and a result is a reason to plan rather than a reason to grieve.
If you have arrived here before reading about the gene itself, BRCA2 and BRCA1 and pancreatic cancer explains what the commonest of these changes actually does, and our complete guide to pancreatic cancer covers the disease itself. What follows stays on one narrower question: what the family does next.
Did you know? NCCN guidance does not stop at the person who was diagnosed. It recommends that germline genetic testing be offered to everyone with pancreatic cancer, whatever their age and whatever their family history looks like — and that where a pathogenic variant is identified, at-risk blood relatives be offered targeted testing for that specific variant, with genetic counselling around it. Cascade testing is therefore part of the guideline, not an optional extra a family has to think to ask for. The targeted test is also simpler than the one that found the change: the laboratory is reading a single known site rather than searching a whole panel, which is why a relative's result is usually quicker and cheaper than the first test in the family was.
Order matters
Who Gets Tested, and In What Order
Cascade testing works outwards from the person who carries the change, one ring at a time. Testing everybody at once is not more thorough — it is simply more expensive, and it tests people whose result was already predictable.
First ring
Parents, brothers, sisters and children
First-degree relatives are offered the targeted test first. Each of them has a one-in-two chance of carrying the same change, and each positive result opens a further branch of the family that can then be tested.
Second ring
Aunts, uncles, nieces, nephews, grandparents
Second-degree relatives are usually approached through whichever first-degree relative tested positive. If a branch tests negative, the people below it in that branch do not need testing at all.
Which side
Work out the side of the family first
These changes come down one parental line, not both. Establishing which side carries it stops half the family being tested for something they were never at risk of inheriting.
Blood relatives only
Spouses and in-laws are not tested
Only blood relatives can inherit the change. A partner who married into the family cannot carry it, although they are very often the person who ends up organising everybody else.
Children
Usually deferred until adulthood
Where a change raises the risk of cancers of adult life, testing is generally deferred until the child is old enough to decide for themselves, because nothing in their care would change before then.
If the carrier has died
Testing can still start with you
When the relative who had cancer was never tested, or is no longer alive, a wider panel is offered to the closest available blood relative instead. The order changes; the logic does not.
The four answers
What a Relative's Result Actually Means
A cascade result is narrower than the original test, which is precisely what makes it useful. It has fewer ways of being ambiguous.
| Result in the relative | What it actually means | What usually follows |
|---|---|---|
| The family change is present | They carry the same inherited change. This is a raised risk across a defined group of cancers, not a diagnosis and not a prediction. | Counselling, a personal risk plan, and a decision about whether structured surveillance is appropriate. Their own children and siblings become testable. |
| The family change is absent | A true negative, and genuinely informative — quite unlike a panel that simply finds nothing. They did not inherit it. | No gene-based surveillance, and their children do not need the test. Ordinary advice applies, and any separate family history is still weighed on its own. |
| A different change turns up | Occasionally a wider panel finds an unrelated variant alongside, or instead of, the one being looked for. | It is interpreted on its own merits, in its own counselling appointment, rather than folded into the family's original result. |
| The family result was uncertain | The original report described a variant of uncertain significance — neither clearly harmful nor clearly harmless. | Cascade testing is not usually offered on an uncertain variant. The family history itself drives the plan until the laboratory reclassifies it. |
The second row is the one families underestimate. A relative who tests negative for a change already known in the family is not being reassured loosely — that branch of the tree can genuinely be closed. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Result Only Helps the Family If It Reaches Them
One conversation turns a laboratory report into a plan for the people it also describes.
What actually happens
What Happens When a Family Brings Us a Known Result
-
A free 45-minute consultation, with the report in front of us
Bring the genetics report itself, not a description of it. The gene, the exact variant and its classification are the three things the whole plan is built on, and a relative's memory of a phone call is not enough to test from.
In-house at CION -
The family tree is drawn properly
Who has had cancer, roughly when in life, and on which side. This is what decides which relatives are offered the test first and which branches can be left alone, and it takes one unhurried conversation rather than a form.
In-house at CION -
Counselling before anybody gives a sample
You should know what each answer would mean before you agree to have it. That includes the uncomfortable part: your result is also information about people who did not ask for it, and deciding how and when to tell them is part of the appointment.
In-house at CION -
Targeted testing arranged, and the report explained plainly
A blood or saliva sample is taken and the single known site is read. We order it, chase it and go through the report line by line in the language you actually speak, with the analysis itself done by an accredited genetics laboratory.
Ordering and counselling in-house at CION -
A positive relative gets a whole plan, not only a pancreas plan
Most of these genes carry risks beyond the pancreas, and for women the breast and ovarian pathways are usually the more immediate part of the plan. Our breast cancer hub and ovarian cancer hub set out what those involve.
Counselling and care planning in-house at CION -
Pancreatic surveillance where it is genuinely indicated
For the smaller group in whom it is appropriate — usually a carrier who also has pancreatic cancer in a close blood relative — imaging is planned with an interval agreed in advance. MRI with MRCP is ordered and reported by CION; endoscopic ultrasound is arranged with our partner centres.
MRI in-house at CION; EUS coordinated with partner centres
Plainly stated
What CION Delivers, and What Is Coordinated Elsewhere
Saying this at the outset saves a difficult conversation later. Your first consultation is free, lasts 45 minutes, and is a genuine review of the report and the family history rather than a booking slot.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: family-history and hereditary-risk assessment; genetic counselling before and after testing, including cascade-testing advice and help with how to tell relatives; the ordering and reporting of targeted single-site testing, and of wider panels where no family variant is documented; the ordering and reporting of pancreatic-protocol CT, MRI with MRCP, CA 19-9 and routine bloods; medical oncology, including combination chemotherapy and, where a BRCA-related change is present, maintenance treatment of the PARP-inhibitor class; radiation, chemoradiation and SBRT; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up. Laboratory analysis of the sample itself is performed by accredited genetics laboratories.
Coordinated with specialist HPB, gastroenterology, endoscopy and nuclear medicine partner centres, and may be billed there: all pancreatic surgery; endoscopic ultrasound and EUS-guided biopsy, which is also part of most inherited-risk surveillance protocols; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we take part in the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre or endoscopy lists, because they are not.
One caution about tests, since families often ask for them by name. CA 19-9 is a blood marker used to follow a cancer that is already known about; it is not a screening test for a well relative, and a normal result in someone with an inherited risk proves very little. Structured surveillance, where it is offered at all, is imaging-led and selective. And if this page has reached you because someone in the family has already been diagnosed, the practical next step is not a gene test at all — it is pancreatic cancer treatment in Hyderabad, where the genetics feed into the plan rather than replacing it.
Bring the genetics report, and a rough list of who in the family has had cancer and roughly when. Those two things settle more in one sitting than months of reading. Book a free consultation or call 1800 202 8726.
Take the next step
Inherited Risk Is One of the Few Things a Family Can Know Early
Knowing who needs testing, and who does not, makes every decision after it simpler. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Family testing after a gene result — your questions answered
What is cascade testing, and how is it different from the first test in the family?
The first test in a family is usually a panel: the laboratory reads many genes at once, because nobody yet knows what it is looking for. Cascade testing is the step that follows a positive result. The specific change has already been identified, so relatives are offered a targeted test that reads one known site in one known gene rather than the whole panel again. It answers a single question - do you carry the family's change or not - and because the laboratory is not searching, the result is generally quicker and cheaper than the original test was. Everything else about it is the same: a blood or saliva sample, and a counselling conversation before and after.
Which relatives should be tested first?
Testing works outwards one ring at a time, starting with first-degree relatives - the parents, brothers, sisters and children of the person who carries the change. Each of them has a one-in-two chance of carrying it, and each positive result opens the branch below them for testing. Second-degree relatives such as aunts, uncles, nieces, nephews and grandparents are usually approached through whichever first-degree relative has tested positive, because if a branch tests negative the people below it in that branch do not need testing at all. It is also worth establishing early which side of the family the change came down, since it travels one parental line rather than both. Only blood relatives can inherit it, so spouses and in-laws are not tested.
My relative's report names a gene change. Do I need the whole panel?
Usually not. If the report names a specific pathogenic or likely pathogenic variant, the targeted single-site test for that exact variant is the appropriate test, and a wider panel tends to add cost and ambiguity without adding much information. There are exceptions. If the family has more than one known change, if cancers are appearing that do not fit the gene identified, or if the original report described only a variant of uncertain significance, a broader test may be the more sensible starting point. This is a decision to make in a counselling appointment with the actual report in front of you, which is why we ask families to bring the document itself rather than a description of what they were told over the phone.
What does a negative result actually mean for me?
More than most people expect. When the change is already known in your family and your targeted test does not find it, that is a true negative - a genuinely informative result, quite unlike a panel that simply finds nothing. You did not inherit the family's change, you cannot pass it on, and your children do not need the test. Gene-based surveillance is not indicated, and your risk returns to roughly that of the general population as far as that gene is concerned. Two things still hold. A separate family history, particularly on the other side of the family, is weighed on its own merits. And ordinary advice still applies to everyone: not smoking, keeping weight and blood sugar in a reasonable range, and getting persistent unexplained symptoms looked at properly rather than waited out.
Should my children be tested, and at what age?
Where an inherited change raises the risk of cancers that appear in adult life, testing is generally deferred until the child is old enough to decide for themselves. The reason is practical rather than protective: nothing in a young child's medical care would change on the strength of the result, so testing early removes their choice without offering anything in return. Some syndromes behave differently and are managed differently, which is one of the questions a counselling appointment exists to answer. What is usually more useful in the meantime is simply making sure the information does not get lost - the gene, the exact variant and the laboratory report, kept somewhere your children can find them - so that they can act on it when the time comes rather than starting the whole search again.
What does CION do for a family with a known gene change, and what happens at the first visit?
The first visit is a free 45-minute consultation with a medical oncologist, and the useful version of it involves two things you bring: the genetics report itself, and a rough account of who in the family has had cancer and roughly when. We draw the family tree, work out which side the change came down, and set out who should be offered the targeted test and in what order. Genetic counselling, the ordering and reporting of targeted and panel germline testing, imaging and CA 19-9 ordering and reporting, medical and radiation oncology, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION across 35+ centres. Endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, PET-CT and DOTATATE PET, and all pancreatic surgery are coordinated with specialist partner centres and may be billed there.
Medical disclaimer: This page explains how cascade genetic testing works for the relatives of someone carrying an inherited cancer gene change, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and on genetic and familial high-risk assessment. It is general information and not an interpretation of any individual report; which relatives should be tested, in what order, and what any result means for them must be discussed with a doctor and a genetic counsellor who have seen the family's own documents. Genetic counselling, cascade-testing advice, the ordering and reporting of targeted and panel germline testing, pancreatic-protocol CT, MRI with MRCP, CA 19-9 and routine bloods, medical and radiation oncology, nutrition and enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION, with laboratory analysis performed by accredited genetics laboratories. Endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, PRRT and all pancreatic surgery are coordinated with specialist HPB, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.